ImmunityBio (IBRX) Non Operating Investment Income (2015 - 2026)

ImmunityBio (IBRX) has reported Non Operating Investment Income for 12 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Investment Income rose 160.88% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $7.8 million (up 35.9% YoY), while the FY2025 annual figure was $6.4 million, down 19.69% from the prior year.
• Non Operating Investment Income rose to $2.3 million in Q1 2026 per IBRX's latest filing, from $2.3 million in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $3.1 million in Q1 2024 and bottomed at -$3.8 million in Q4 2022.
• Historically, Non Operating Investment Income has averaged $866764.7 across 5 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2022 — Non Operating Investment Income tumbled 916.95% — and 2024, when it jumped 5037.14%.
• ImmunityBio's Non Operating Investment Income stood at -$3.8 million in 2022, then jumped by 112.69% to $484000.0 in 2023, then surged by 145.25% to $1.2 million in 2024, then jumped by 93.6% to $2.3 million in 2025, then grew by 0.7% to $2.3 million in 2026.
• Business Quant data shows IBRX's Non Operating Investment Income at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.